Evotec stock holds just above its 52-week low as profit warning and Q2 2026 loss reset guidance
Published on 08/26/2026 at 06:43 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Evotec SE stock (ISIN DE0005664809) is trading in the low single-digit euro range in late August 2026 after a recent profit warning and weak second-quarter 2026 figures pushed the drug discovery specialist into a deeper adjusted EBITDA loss and prompted a sharp cut to full-year guidance as of August 25, 2026. Recent corporate coverage highlights ongoing pressure on investor sentiment as the share price hovers just above its 52-week low.
Half-year 2026 figures confirm a weaker trajectory
An earnings overview published on August 25, 2026 shows that Evotec generated group revenue of EUR300.1 million in the first half of 2026, with the second quarter contributing EUR143.5 million and underscoring the scale of the business in the current year. In the same half-year period, group revenue contracted 19.2 percent compared with the prior-year period, signaling a clear slowdown from the company’s previous growth pace.
The segment breakdown for the first half of 2026 points to broad-based pressure. The Discovery and Preclinical Development business delivered EUR228.1 million in revenue in the first six months, which represents a 15.2 percent decline versus the prior-year period and illustrates how softer demand and project timing are weighing on Evotec’s core operations. The Just-Evotec Biologics segment recorded EUR72.3 million in revenue in the same interval, also down year-over-year, adding to the overall contraction in top-line performance.
Profitability deteriorated more sharply than revenue. Evotec reported an adjusted EBITDA loss of EUR42.7 million for the first half of 2026, swinging from a negative EUR1.9 million a year earlier and highlighting the impact of operational issues and restructuring charges on the income statement. At the second-quarter level, sales fell 16.2 percent to EUR143.5 million, while adjusted EBITDA came in at a loss of EUR20.8 million, confirming that the profit warning was grounded in a tangible earnings setback.
Guidance cut and restructuring weigh on valuation
Following the profit warning in late July 2026, Evotec’s management is now guiding for full-year 2026 revenue between EUR570 million and EUR610 million, down from earlier ambitions and explicitly reflecting the weaker first half and a more cautious view of the second half. The same guidance framework projects adjusted EBITDA for 2026 to land in a loss range of EUR70 million to EUR105 million, a substantial reversal from the modest negative result seen in the prior year and a key driver of the current rerating in the stock.
Restructuring measures are adding to the earnings drag. Recent coverage indicates that the bill for Evotec’s restructuring program is approaching EUR100 million, a significant figure relative to the size of the business and one that investors must factor into their earnings and cash flow expectations. When a company with half-year revenue of EUR300.1 million carries a restructuring burden close to EUR100 million and guides for a full-year adjusted EBITDA loss of up to EUR105 million, the equity story shifts from growth toward recovery and balance-sheet resilience.
The market reaction to the half-year numbers and guidance reset was swift. In trading following the release, Evotec shares touched EUR3.33, a level described as not seen in a decade, emphasizing how far the valuation has compressed from earlier years when the company was viewed as a high-growth platform. Subsequent trading saw the stock settle around EUR3.26, leaving it just 2.3 percent above the 52-week low of EUR3.19 recorded in mid-July 2026. That narrow gap between the current share price and the recent low underscores how fragile confidence remains.
Late August 2026 price action and trading context
Equity market commentary dated August 24, 2026 documents that Evotec shares on Xetra were quoted at EUR3.28 at 4:28 p.m. local time, representing a decline of 2.1 percent versus the prior close and extending a pattern of trading in the low single-digit euro range in late August 2026. A separate Xetra session snapshot on August 25, 2026 reported the stock at EUR3.30 at 12:28 p.m. local time, showing a 0.9 percent intraday gain and highlighting that short-term moves have been modest compared with the larger downward trend driven by fundamentals.
The combination of a share price around EUR3.26 and a 52-week low at EUR3.19 means the stock is trading only 2.3 percent above its weakest point over the past year, according to recent coverage. For investors, that comparison crystallizes the current risk-reward profile: the downside experienced since the profit warning has already been substantial, but the proximity to the low suggests the market has not yet fully embraced the revised outlook or the company’s restructuring plan.
Earlier in 2026, market data from the Xetra session show Evotec quoted at EUR5.175 at 10:51 a.m. on May 22, 2026, with trading volume of 782,178 shares on that venue during the session. Viewed against the late August level around EUR3.26, this indicates that the stock has fallen more than 35 percent from its May price, underscoring how swiftly sentiment turned once operational challenges and guidance cuts came to the fore. The shift from trading above EUR5 in May to trading close to EUR3.20 in August reflects both the earnings disappointment and heightened uncertainty around the pace of recovery.
Evotec’s drug discovery platform and biologics capabilities
Evotec SE operates a broad drug discovery and development platform that supports pharmaceutical and biotech partners across multiple therapeutic areas. The Discovery and Preclinical Development segment, which delivered EUR228.1 million in revenue in the first half of 2026, encompasses services ranging from target identification and validation to hit finding, lead optimization, and preclinical testing. The double-digit 15.2 percent decline in this segment’s revenue versus the prior-year period underlines how changes in client budgets and project timelines can quickly translate into slower growth for outsourced R&D providers.
The Just-Evotec Biologics segment, which generated EUR72.3 million in revenue in the same half-year period, focuses on biologics discovery, development, and manufacturing, including advanced modalities such as antibodies and other large molecules. While this business also faced year-over-year revenue declines, its presence gives Evotec exposure to a structurally growing area of the pharmaceutical market, where demand for flexible biologics capacity and expertise remains high over the long term. For investors, the combination of falling short-term revenue and attractive structural positioning creates a nuanced picture: near-term earnings risk contrasted with longer-term opportunity.
Across both segments, Evotec leverages integrated platforms and proprietary technologies to accelerate drug discovery for partners. The company’s strategic programs, including investments in new sites and technologies, have contributed to the adjusted EBITDA loss of EUR42.7 million in the first half of 2026, but they are aimed at strengthening the platform’s competitiveness over time. The tension between investing for growth and protecting margins is central to the current investment case, particularly as management now expects adjusted EBITDA to remain in a loss range of EUR70 million to EUR105 million for the full year.
Stock level and investor takeaway
As of August 25, 2026, late-August trading data and corporate coverage indicate that Evotec stock on Xetra is changing hands in the low single-digit euro range, with recent quotes around EUR3.26 and a 52-week low at EUR3.19 set in mid-July 2026. The move from EUR5.175 on May 22, 2026 to roughly EUR3.26 in late August translates into a decline of more than one third over that period, driven by a half-year revenue contraction of 19.2 percent, an adjusted EBITDA loss of EUR42.7 million, and a reset of full-year guidance to revenue of EUR570 million to EUR610 million with an expected adjusted EBITDA loss of EUR70 million to EUR105 million. For investors, Evotec stock now reflects a turnaround narrative anchored in restructuring and margin repair rather than near-term earnings growth.
Fact box
Company: Evotec SE
ISIN: DE0005664809
Ticker: EVT
Exchange: Xetra
Sector / Industry: Biotechnology and pharmaceutical services
Index membership: TecDAX
